Literature DB >> 25616912

Isolation and characterization of antibody fragments selective for toxic oligomeric tau.

Huilai Tian1, Eliot Davidowitz2, Patricia Lopez2, Ping He1, Philip Schulz1, James Moe2, Michael R Sierks3.   

Abstract

Oligomeric tau species are important in the onset and progression of Alzheimer's disease (AD), as they are neurotoxic and can propagate tau-tangle pathology. Therefore, reagents that selectively recognize different key morphologies of tau are needed to help define the role of tau in AD and related diseases. We utilized a biopanning protocol that combines the binding diversity of phage-displayed antibody libraries with the powerful imaging capability of atomic force microscopy to isolate single-chain antibody fragments (scFvs) that selectively bind toxic oligomeric tau. We isolated 3 different antibody fragments that bind oligomeric but not monomeric or fibrillar tau. The scFvs differentiate brain tissue homogenates of both 3×TG and tau-AD mice from wild-type mice, detecting oligomeric tau at much earlier ages than when neurofibrillary tangles are typically detected. The scFvs also distinguish human postmortem AD brain tissue from cognitively normal postmortem human brain tissue, demonstrating the potential of this approach for developing biomarkers for early detection and progression of AD.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Alzheimer's disease; Antibody fragments; Biomarker; Brain tissue; Immunotherapy; Oligomeric tau; Phage display; Toxic tau aggregates; scFv

Mesh:

Substances:

Year:  2014        PMID: 25616912      PMCID: PMC4346425          DOI: 10.1016/j.neurobiolaging.2014.12.002

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN: 0197-4580            Impact factor:   4.673


  96 in total

1.  High level production of soluble single chain antibodies in small-scale Escherichia coli cultures.

Authors:  S M Kipriyanov; G Moldenhauer; M Little
Journal:  J Immunol Methods       Date:  1997-01-15       Impact factor: 2.303

Review 2.  Tau oligomers and tau toxicity in neurodegenerative disease.

Authors:  Sarah M Ward; Diana S Himmelstein; Jody K Lancia; Lester I Binder
Journal:  Biochem Soc Trans       Date:  2012-08       Impact factor: 5.407

3.  Identification of oligomers at early stages of tau aggregation in Alzheimer's disease.

Authors:  Cristian A Lasagna-Reeves; Diana L Castillo-Carranza; Urmi Sengupta; Jose Sarmiento; Juan Troncoso; George R Jackson; Rakez Kayed
Journal:  FASEB J       Date:  2012-01-17       Impact factor: 5.191

4.  Characterizing antibody specificity to different protein morphologies by AFM.

Authors:  Min S Wang; Andleeb Zameer; Sharareh Emadi; Michael R Sierks
Journal:  Langmuir       Date:  2009-01-20       Impact factor: 3.882

Review 5.  Common mechanisms of amyloid oligomer pathogenesis in degenerative disease.

Authors:  Charles G Glabe
Journal:  Neurobiol Aging       Date:  2006-02-14       Impact factor: 4.673

6.  Stepwise proteolysis liberates tau fragments that nucleate the Alzheimer-like aggregation of full-length tau in a neuronal cell model.

Authors:  Y P Wang; J Biernat; M Pickhardt; E Mandelkow; E-M Mandelkow
Journal:  Proc Natl Acad Sci U S A       Date:  2007-05-29       Impact factor: 11.205

Review 7.  Tau phosphorylation: the therapeutic challenge for neurodegenerative disease.

Authors:  Diane P Hanger; Brian H Anderton; Wendy Noble
Journal:  Trends Mol Med       Date:  2009-02-24       Impact factor: 11.951

Review 8.  Role of tau protein in both physiological and pathological conditions.

Authors:  Jesus Avila; Jose J Lucas; Mar Perez; Felix Hernandez
Journal:  Physiol Rev       Date:  2004-04       Impact factor: 37.312

9.  Small misfolded Tau species are internalized via bulk endocytosis and anterogradely and retrogradely transported in neurons.

Authors:  Jessica W Wu; Mathieu Herman; Li Liu; Sabrina Simoes; Christopher M Acker; Helen Figueroa; Joshua I Steinberg; Martin Margittai; Rakez Kayed; Chiara Zurzolo; Gilbert Di Paolo; Karen E Duff
Journal:  J Biol Chem       Date:  2012-11-27       Impact factor: 5.157

Review 10.  Ribosome gymnastics--degree of difficulty 9.5, style 10.0.

Authors:  J F Atkins; R B Weiss; R F Gesteland
Journal:  Cell       Date:  1990-08-10       Impact factor: 41.582

View more
  13 in total

Review 1.  Neuronally expressed anti-tau scFv prevents tauopathy-induced phenotypes in Drosophila models.

Authors:  Senthilkumar Krishnaswamy; Huai-Wei Huang; Isabella S Marchal; Hyung Don Ryoo; Einar M Sigurdsson
Journal:  Neurobiol Dis       Date:  2020-01-23       Impact factor: 5.996

2.  CNS disease-related protein variants as blood-based biomarkers in traumatic brain injury.

Authors:  Stephanie M Williams; Carrie Peltz; Kristine Yaffe; Philip Schulz; Michael R Sierks
Journal:  Neurology       Date:  2018-10-09       Impact factor: 9.910

3.  Novel Brain-Penetrating Single Chain Antibodies Directed Against 3RTau for the Treatment of Alzheimer's Disease and Related Dementias.

Authors:  Brian Spencer; Robert A Rissman; Cassia Overk; Eliezer Masliah
Journal:  Methods Mol Biol       Date:  2022

4.  Visualizing and trapping transient oligomers in amyloid assembly pathways.

Authors:  Emma E Cawood; Theodoros K Karamanos; Andrew J Wilson; Sheena E Radford
Journal:  Biophys Chem       Date:  2020-11-10       Impact factor: 2.352

5.  TDP-43 protein variants as biomarkers in amyotrophic lateral sclerosis.

Authors:  Stephanie M Williams; Galam Khan; Brent T Harris; John Ravits; Michael R Sierks
Journal:  BMC Neurosci       Date:  2017-01-25       Impact factor: 3.288

6.  Pacific Biosciences Sequencing and IMGT/HighV-QUEST Analysis of Full-Length Single Chain Fragment Variable from an In Vivo Selected Phage-Display Combinatorial Library.

Authors:  Audrey Hemadou; Véronique Giudicelli; Melissa Laird Smith; Marie-Paule Lefranc; Patrice Duroux; Sofia Kossida; Cheryl Heiner; N Lance Hepler; John Kuijpers; Alexis Groppi; Jonas Korlach; Philippe Mondon; Florence Ottones; Marie-Josée Jacobin-Valat; Jeanny Laroche-Traineau; Gisèle Clofent-Sanchez
Journal:  Front Immunol       Date:  2017-12-20       Impact factor: 7.561

Review 7.  Tau-mediated Neurodegeneration and Potential Implications in Diagnosis and Treatment of Alzheimer's Disease.

Authors:  Xi-Lin Wu; Juan Piña-Crespo; Yun-Wu Zhang; Xiao-Chun Chen; Hua-Xi Xu
Journal:  Chin Med J (Engl)       Date:  2017-12-20       Impact factor: 2.628

8.  HybriFree: a robust and rapid method for the development of monoclonal antibodies from different host species.

Authors:  Gaily Kivi; Kaupo Teesalu; Jüri Parik; Elen Kontkar; Mart Ustav; Liis Noodla; Mart Ustav; Andres Männik
Journal:  BMC Biotechnol       Date:  2016-01-08       Impact factor: 2.563

Review 9.  Expanding the Repertoire of Biomarkers for Alzheimer's Disease: Targeted and Non-targeted Approaches.

Authors:  Douglas Galasko
Journal:  Front Neurol       Date:  2015-12-16       Impact factor: 4.003

Review 10.  Recombinant Antibody Fragments for Neurodegenerative Diseases.

Authors:  Karen Manoutcharian; Roxanna Perez-Garmendia; Goar Gevorkian
Journal:  Curr Neuropharmacol       Date:  2017       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.